腺病毒载体在肿瘤基因治疗和基因疫苗领域的应用研究进展  

Application of adenovirus vector in cancer gene therapy and vaccination

作　　者：谢谦 高祥[2] 王祎 Xie Qian;Gao Xiang;Wang Yi(Kindos Pharmaceutical Co.Ltd,Chengdu 611731,Sichuan,China;Department of Neurological Surgery,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China;Department of Pathophysiology,Sichuan University,Chengdu 610041,Sichuan,China)

机构地区：[1]成都健进制药有限公司,四川成都611731 [2]四川大学华西医院神经外科,四川成都610041 [3]四川大学华西基础医学与法医学院病理生理教研室,四川成都610041

出　　处：《生物医学转化》2021年第1期83-88,94,共7页Biomedical transformation

基　　金：国家自然科学基金地区项目(31860287);四川省科技厅重点研发项目(2021YFS0051)。

摘　　要：腺病毒载体是目前应用最为广泛的基因治疗病毒载体之一。相较其他病毒载体,腺病毒具有较高的基因转导效率,广泛的组织亲和性,不整合入宿主基因组等优点。腺病毒可以被改造为复制缺陷病毒载体和选择性复制的溶瘤病毒载体。腺病毒载体较强的免疫原性使其可以被应用于基因疫苗和抗癌治疗中。目前众多的临床试验都证实了腺病毒载体在上述治疗试验中的安全性和有效性。Adenovirus vector is one of the most widely used viral vectors for gene therapy.Compared with other viral vectors,adenovirus has various advantages such as high transduction effi ciency,broad tropism for diff erent tissues and epichromosomal persistence in the host cell,etc.Adenovirus vectors can be modifi ed as replication-deficient and replication-selective oncolytic virus vector.The strong immunogenicity of adenovirus vector makes it suitable to be applied in genetic vaccines and anti-cancer therapies.At present,many clinical trials have confirmed the safety and effectiveness of adenovirus vector in the above-mentioned therapeutic attempts.

关 键 词：基因治疗 腺病毒 溶瘤病毒 基因疫苗 

分 类 号：Q812[生物学—生物工程]